PUBLICATIONS Before 2005

Metabolic changes in the basal ganglia of patients with Huntington’s disease: an in situ hybridization study of cytochrome oxidase subunit I mRNA.

Gourfinkel-An I., Vila M., Faucheux B., Duyckaerts C., Viallet F., Hauw J.J., Brice A., Agid Y. and Hirsch E.C.
Journal of Neurochemistry 80(3):466-76 (2002)

Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease.

Wu D.C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D.K., Ischiropoulos H. and Przedborski S.
Journal of Neuroscience 22(5):1763-71 (2002)

Tyrosine hydroxylase.

Jackson-Lewis V., Vila M., and Przedborski S.
Wiley Encyclopedia of Molecular Medicine p.3283-3293 (2002)

Glial cell response: A pathogenic factor in Parkinson’s disease.

Wu D.C., Tieu K., Cohen O., Choi D.K., Vila M., Jackson-Lewis V., Teismann P., Przedborski S.
Journal of Neurovirology 8(6):551-8 (2002)

LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa-induced motor fluctuations in parkinsonian rats.

Marin C., Jiménez A., Bonastre M., Vila M., Hirsch E.C., Agid Y. and Tolosa E.
Synapse 42(1):40-47 (2001)

Recruitment of the mitochondrial-dependent apoptotic pathway in amyotrophic lateral sclerosis.

Guegan C., Vila M., Rosoklija G., Hays A.P. and Przedborski S.
Journal of Neuroscience 21(17):6569-6576 (2001)

Lack of nigral pathology in transgenic mice expressing human a-synuclein driven by the tyrosine hydroxylase promoter.

Matsuoka Y.*, Vila M.*, Lincoln S., McCormack A., Picciano M., LaFrancois J., Yu X., Dickson D., Langston W.J., McGowan E., Farrer M., Hardy J., Duff K., Przedborski S. and Di Monte D.A.
Neurobiology of Disease 8:535-539 (2001)

Bax ablation prevents dopaminergic neurodegeneration in the MPTP mouse model of Parkinson´s disease.

Vila M., Jackson-Lewis V., Vukosavic S., Djaldetti R., Liberatore G., Offen D., Korsmeyer S.J. and Przedborski S.
Proceedings of the National Academy of Sciences USA 98(5):2837-2842 (2001)

Oxidative post-translational modifications of -synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson’s disease.

Przedborski S., Chen Q., Vila M., Giasson B.I., Djaldetti R., Vukosavic S., Souza J.M., Jackson-Lewis V., Lee V.M.Y. and Ischiropoulos H.
Journal of Neurochemistry 76:637-640 (2001)

The last decade in Parkinson’s disease research: basic sciences.

Przedborski S. and Vila M.
Advances in Neurology 86:177-186 (2001)

Related Links